Introduction {#S0001}
============

Heart failure (HF) affects nearly 6 million people in the US, and the prevalence is expected to increase over the next decade.[@CIT0001] Because HF is associated with substantial morbidity and mortality, and because most patients lack a curative treatment option, modifiable risk factors that may serve as potential therapeutic targets need to be identified.[@CIT0002] Previous studies have suggested an association between elevated triglycerides (TG) and increased risk of HF.[@CIT0002],[@CIT0003] In one study, stepwise higher TG (range=88--≥440 mg/dL) were associated with stepwise higher HF risk (hazard ratio \[HR\] range=1.32--2.59) after adjustment for multiple variables.[@CIT0002] However, because reported data on the relationship between TG and HF are inconsistent---potentially because appropriate populations with the highest TG were not examined---further study is warranted.[@CIT0002]

High-risk statin-treated patients with elevated TG and generally controlled low-density lipoprotein cholesterol (LDL-C) are commonly encountered in clinical practice and are increasing in number because of the increasing prevalence of diabetes and obesity. A better understanding of the prevalence, health burden, direct healthcare costs, resource utilization, and rate of new HF diagnoses associated with this population is needed to optimize management. Previously, we reported the real-world impact of elevated (≥150 mg/dL) and high (200−499 mg/dL) TG on cardiovascular (CV) risk and health economic outcomes in patients from the Optum Research Database.[@CIT0004],[@CIT0005] Here we report a secondary objective of that study, the real-world impact of elevated and high TG on risk of HF in high-risk statin-treated patients.

Methods {#S0002}
=======

Study Design {#S0002-S2001}
------------

This is a report of a secondary objective of an Optum Research Database retrospective analysis. Optum is a de-identified database containing commercial and Medicare advantage claims (medical and pharmacy information) for \>160 million people. The retrospective analysis design has been described in detail.[@CIT0004],[@CIT0005] Briefly, eligible patients were ≥45 years old with: documented diabetes and/or atherosclerotic CV disease; ≥1 statin therapy claim between January 1, 2010 and December 31, 2010; ≥6 months of baseline data prior to first statin claim. Patients with niacin remaining from a recent prescription fill on the index date were ineligible. Patients were followed for ≥6 months beginning on the index date to the earliest of the following: study end (March 31, 2016), date of insurance plan disenrollment, or death.

Study Cohorts and Endpoints {#S0002-S2002}
---------------------------

Assessments were made in three cohorts: 1) an elevated-TG cohort with TG ≥150 mg/dL at the most recent laboratory visit prior to the index date; 2) a high-TG sub-cohort with TG 200--499 mg/dL; and 3) comparator cohorts with TG \<150 mg/dL and high-density lipoprotein cholesterol (HDL-C) \>40 mg/dL. Elevated-TG cohort patients were matched to patients in the comparator cohort in a 1:1 ratio. Unmatched patients were excluded from descriptive analyses.

The primary objective was occurrence of major CV events (ie, composite of CV-related death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or unstable angina in the follow-up period). Secondary objectives included quantification of direct healthcare costs (US\$) and resource utilization in the follow-up period. The findings of these objectives have previously been reported.[@CIT0004],[@CIT0005] Here we report the additional secondary objective of the effects of TG on HF risk.

Statistical Analysis {#S0002-S2003}
--------------------

Details of the statistical analysis have been previously reported.[@CIT0004]--[@CIT0006] [Table 1](#T0001){ref-type="table"} contains a list of the statistical methodology employed.Table 1Statistical MethodologyItemStatistical MethodologyStudy variablesAnalyzed descriptively and reported for the overall study sample, as well as stratified and statistically compared by cohortContinuous variablesMeans and standard deviationsDirect healthcare cost and resource utilizationDescriptive techniques that account for the length of observation time, such as per patient per monthComparison of categorical measuresRao-Scott test and chi-square testComparison of continuous measuresStudent\'s *t*-test and analysis of varianceMultivariate pre-match analysesCox proportional hazards model to calculate HRs for time-to-event analyses of the effects of the covariatesTime-to-event probabilitiesKaplan-Meier analysesClustered *P*-valuesCox proportional hazard model with cohort as independent variable (alpha\<0.05)Descriptive analysesPropensity score analysis to create a matched comparator study cohort similar to the analysis cohort, but without elevated or high TG, by controlling for confounding relationships^a^; propensity score matching was performed using a greedy match algorithm[@CIT0006][^1]

Results {#S0003}
=======

Patients {#S0003-S2001}
--------

The demographic and baseline characteristics of patients in each cohort have been described previously.[@CIT0004],[@CIT0005] Approximately 1.6 million statin-treated patients with ≥1 prescription claim for a statin were identified from the Optum Research Database. Following application of inclusion and exclusion criteria and after propensity score matching, the elevated-TG cohort consisted of 23,181 patients and the high-TG sub-cohort consisted of 10,990 patients, with matching numbers of patients in their respective comparator cohorts.[@CIT0004],[@CIT0005] There were few clinically important differences between the elevated-TG or high-TG cohorts and their respective propensity score-matched comparator cohorts with regard to patient demographics and characteristics or baseline comorbidities, except for a difference in lipid levels in accordance with the cohort inclusion criteria ([Table 2](#T0002){ref-type="table"}).[@CIT0004],[@CIT0005] In the elevated-TG and matched comparator cohorts, respectively, mean age was 62.2 and 62.6 years, 30% and 29% had atherosclerotic CV disease, and 15% and 14% had peripheral artery disease. In both cohorts, 50% were women, 84% had diabetes, 79% had hypertension, and 12% had renal disease ([Table 2](#T0002){ref-type="table"}). Similar results were observed in the sub-cohort analysis of patients with TG 200--499 vs the matched comparators ([Table 2](#T0002){ref-type="table"}).Table 2Patient Demographics, Characteristics, and Baseline ComorbiditiesElevated-TG^a^ n=23,181Comparator^a^ n=23,181*P*-valueHigh-TG^b^ n=10,990Comparator^b^ n=10,990*P*-valueAge, mean (SD), years62.2 (9.6)62.6 (9.9)\<0.00161.7 (9.6)62.2 (9.9)\<0.001Female, n (%)11,518 (49.7)11,467 (49.5)0.2445,433 (49.4)5,424 (49.4)0.769Insurance type, n (%) Commercial15,823 (68.3)15,855 (68.4)0.4617,589 (69.1)7,571 (68.9)0.556 Medicare7,358 (31.7)7,326 (31.6)0.4613,401 (30.9)3,419 (31.1)0.556Duration of follow-up, mean (SD), months41.4 (23.7)42.5 (23.9)\<0.00141.3 (23.8)42.1 (23.9)0.018Baseline^c^ lipid profile, mean (SD), mg/dL TG220.31 (77.4)97.9 (28.9)\<0.001263.8 (60.2)98.2 (29.2)\<0.001 LDL-C104.6 (41.1)100.9 (35.0)\<0.001106.1 (43.2)101.7 (34.7)\<0.001 HDL-C42.3 (10.2)55.1 (12.2)\<0.00140.4 (9.3)55.0 (12.4)\<0.001 Total cholesterol190.2 (46.6)175.4 (38.8)\<0.001198.2 (47.9)176.3 (38.6)\<0.001 Non-HDL-C^d^147.9 (44.2)120.4 (36.5)\<0.001157.9 (45.2)121.2 (36.3)\<0.001Baseline comorbidities, n (%) Diabetes19,392 (83.7)19,478 (84.0)0.0179,326 (84.86)9,375 (85.30)0.048 ASCVD6,915 (29.8)6,800 (29.3)0.0093,185 (28.98)3,141 (28.58)0.156 MI495 (2.1)411 (1.8)0.003235 (2.14)189 (1.72)0.020 Stroke750 (3.2)674 (2.9)0.005349 (3.18)323 (2.94)0.177 Angina1,225 (5.3)1,179 (5.1)0.284571 (5.20)554 (5.04)0.562 Coronary revascularization600 (2.6)506 (2.2)0.002299 (2.72)213 (1.94)\<0.001 Peripheral artery disease3,384 (14.6)3,317 (14.3)0.1041,561 (14.20)1,550 (14.10)0.704 Heart failure1,258 (5.4)1,088 (4.7)\<0.001626 (5.70)519 (4.72)\<0.001 Atrial fibrillation1,133 (4.9)989 (4.3)0.001527 (4.80)472 (4.29)0.070 Hypertension18,346 (79.1)18,375 (79.3)0.4628678 (78.96)8,723 (79.37)0.106 Renal disease2832 (12.2)2782 (12.0)0.1961322 (12.03)1,314 (11.96)0.767[^2][^3]

Impact of TG on Heart Failure {#S0003-S2002}
-----------------------------

The rate of new HF diagnosis per unit of time (secondary study objective) was 19% higher in the elevated-TG cohort (HR=1.192; 95% CI=1.134--1.252; *P*\<0.001) and 24% higher in the high-TG cohort (HR=1.235; 95% CI=1.160--1.315; *P*\<0.001) compared with the respective comparator cohorts ([Figure 1](#F0001){ref-type="fig"}). Kaplan-Meier analysis showed that freedom from new onset HF was significantly higher in the comparator cohort than in the elevated- or high-TG cohorts ([Table 3](#T0003){ref-type="table"}).Table 3Freedom from New Diagnoses of Heart Failure in Statin-Treated Patients with High Cardiovascular Risk and Elevated or High Triglycerides vs Comparators (Kaplan-Meier Analysis)Cohort0.5 Year1 Year2 Years3 Years4 Years5 YearsClustered *P*-valueElevated triglycerides^a^0.9743 (22,508)0.9541 (18,839)0.9179 (14,052)0.8869 (11,033)0.8588 (7,343)0.8337 (5,564)\<0.001Comparator^a^0.9785 (22,593)0.9609 (19,106)0.9324 (14,524)0.9057 (11,615)0.8808 (7,910)0.8554 (6,098)High triglycerides^b^0.9740 (10,667)0.9531 (8,907)0.9172 (6,642)0.8880 (5,216)0.8587 (3,487)0.8303 (2,624)\<0.001Comparator^b^0.9793 (10,729)0.9623 (9,022)0.9342 (6,832)0.9054 (5,432)0.8814 (3,707)0.8585 (2,867)[^4] Figure 1Effects of triglycerides on new diagnoses of heart failure in statin-treated patients with high cardiovascular risk^a^. New diagnosis of HF required diagnosis in the follow-up period without prior evidence of HF.**Notes:** ^a^Multivariate analysis using Cox proportional hazard model. Separate pre-match multivariate analyses of heart failure were performed. Covariates included TG cohort, as represented here, along with age (45--54, 55--64, ≥65 years), sex, insurance coverage type, geographic region of enrollment, baseline clinical characteristics (diabetes, ASCVD, LDL-C laboratory result in relation to median), and baseline medication use (fibrate, prescription omega-3, both, and neither). ^b^Elevated-TG pre-match cohort: TG ≥150 mg/dL (n=24,043 patients); comparator pre-match cohort: TG \<150 mg/dL and HDL-C \>40 mg/dL (n=30,218 patients). ^c^High-TG pre-match cohort: TG 200--499 mg/dL (n=11,657 patients); comparator pre-match cohort: TG \<150 mg/dL and HDL-C \>40 mg/dL (n=30,218 patients).**Abbreviations:** ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; CV, cardiovascular; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides.

Discussion {#S0004}
==========

This real-world analysis of administratively derived data from more than 45,000 patients in the Optum Research Database found that both elevated TG (≥150 mg/dL) and high TG (200--499 mg/dL) were significant predictors (19% and 24% increased risk, respectively) of a new HF diagnosis in patients with high CV risk. These data are consistent with previous studies reporting an association between elevated TG and increased HF risk.[@CIT0002],[@CIT0003] Our HF findings were a secondary objective of a study that evaluated the real-world impact of elevated and high TG on CV and health economic outcomes in patients from the Optum Research Database.[@CIT0004],[@CIT0005]

In our previous analyses of the statin-treated patients at high CV risk with elevated or high TG and generally controlled LDL-C from the Optum Research Database in this report, we found worse CV and health economic outcomes among the patients with elevated and high TG than the comparator patients with well-managed TG.[@CIT0004],[@CIT0005] In the high-TG sub-cohort, multivariate analysis showed that the composite endpoint of major CV events occurred at a 34.9% higher rate compared with the matched comparator cohort, with a HR (95% CI) of 1.35 (1.225--1.485) (*P*\<0.001).[@CIT0005] Total direct healthcare costs and inpatient hospital visits were also significantly higher in the high-TG sub-cohort. The mean (SD) total monthly direct healthcare cost was 15% higher in the high-TG cohort (\$1,462 \[\$3,354\]) than in the comparator cohort (\$1,279 \[\$2,628\]; *P*\<0.001).[@CIT0005] Extrapolating from the per-patient-per-month average total direct healthcare costs across the variable follow-up time in this study, the approximate average annual direct cost difference between the elevated-TG and comparator cohorts was \$24 million per year; this translates to \$220 million per year per 100,000 patients.[@CIT0005] The frequency of inpatient visits was higher in the high-TG sub-cohort than in the comparator cohort (34.0% vs 30.4%; *P*\<0.001).[@CIT0005]

The association of high TG with HF may be direct, indirect, or both. Elevated TG are a marker of insulin resistance and metabolic syndrome, and hence occur relatively commonly in patients with diabetes mellitus.[@CIT0007],[@CIT0008] Hypertriglyceridemia is also a marker of elevated serum levels of remnant lipoproteins (small very-low-density and intermediate-density lipoproteins), which are known to be atherogenic and pro-inflammatory.[@CIT0009]--[@CIT0011] Hypertriglyceridemia correlates with increased risk for atherosclerotic disease and its sequelae;[@CIT0004],[@CIT0005],[@CIT0012] hence, it is possible that the hypertriglyceridemia phenotype confers increased risk for HF by increasing risk for ischemic cardiomyopathy. Acquired hypertriglyceridemia is a manifestation of insulin resistance, which correlates strongly with expansion of epicardial fat pad volume; increased epicardial adiposity, in turn, is associated with accelerated atherogenesis and lipotoxic cardiomyopathy.[@CIT0013] An augmented HF risk in patients with hypertriglyceridemia may also arise from direct toxic effects of TG and their constituent fatty acids in the subendothelial space and myocardium.[@CIT0014] Oxidized fatty acids induce proinflammatory and pro-oxidative effects. Although other studies have shown that elevated TG correlate with increased risk for HF,[@CIT0002],[@CIT0015]--[@CIT0017] the current study is the first to show this relationship in high-risk statin-treated patients with well-controlled LDL-C. Our data do not allow us to discern which types of HF are increased in our cohort. This will require additional investigation. It will be important to undertake randomized trials and ascertain if reduction of TG in patients with hypertriglyceridemia reduces risk of new-onset HF.

A strength of this study is that data were obtained from a real-world setting that encompassed a large number of patients drawn from actual clinical practice and may thus be more reflective of actual use than is evidenced from clinical trials.[@CIT0018],[@CIT0019] However, these data, based on claims from a managed care health plan, may not be generalizable. Other concerns with a real-world study are inaccurate recording of health events, missing data, and uncertainty about their internal validity.[@CIT0020] Certain costs to patients, such as transportation and missed work days, were also not captured in claims data. Further, because of the large sample size, small differences may show statistical significance without being clinically relevant. It should be noted that this analysis was designed to assess the clinical and health economic burden posed by elevated TG despite generally controlled LDL-C, rather than to assess the potential effects of any adjunctive therapy.

Conclusion {#S0005}
==========

This real-world analysis showed that statin-treated patients with high CV risk and elevated TG (≥150 mg/dL) or high TG (200--499 mg/dL) had worse CV and health economic outcomes than patients with normal TG (\<150 mg/dL) and HDL-C \>40 mg/dL. Both elevated TG and high TG were significant predictors of new-onset HF (19% and 24% increased risk, respectively). These data are consistent with other studies reporting an association between elevated TG and increased HF risk.[@CIT0002],[@CIT0003] As the prevalence and burden of HF continue to increase, additional study is warranted to gain further insight into the relationship between TG levels and HF risk.
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[^1]: **Note:** ^a^The final list of propensity score model variables was based on review of pre-matching descriptive analyses of patient characteristics and pre-index measures including age, gender, type of insurance, region, baseline direct medical cost, low-density lipoprotein cholesterol level relative to the median, baseline use of omega-3 fatty acids, fibrates, or statins, and diagnoses including diabetes, atherosclerotic CV disease, hypertension, stroke, peripheral artery disease, and renal disease.

[^2]: **Notes:** Data from these studies.[@CIT0004],[@CIT0005] Rao-Scott test was used for binary measures. Robust standard errors were used for continuous measures. ^a^Elevated TG ≥150 mg/dL and matched comparator with TG \<150 mg/dL and HDL-C \>40 mg/dL. ^b^High TG 200--499 mg/dL and matched comparator with TG \<150 mg/dL and HDL-C \>40 mg/dL. ^c^Baseline period excludes index date. ^d^Calculated by subtracting HDL-C result from total cholesterol. This value was not calculated unless patients had both HDL-C and total cholesterol laboratory result in period.

[^3]: **Abbreviations:** ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; non-HDL-C, non-high-density lipoprotein cholesterol; SD, standard deviation; TG, triglycerides.

[^4]: **Notes:** Values represent probability of freedom from new diagnoses of heart failure (number of patients at risk). New diagnosis of HF required diagnosis in the follow-up period without prior evidence of HF. Clustered *P*-values were calculated using Cox proportional hazard model with cohort as independent variable. ^a^Elevated TG ≥150 mg/dL and comparator with TG \<150 mg/dL and HDL-C \>40 mg/dL. ^b^High TG 200--499 mg/dL and comparator with TG \<150 mg/dL and HDL-C \>40 mg/dL.
